Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy

Japanese Journal of Ophthalmology

Volumn 56, Issue 6, 2012, Pages 608-612

  Semeraro, Francesco ^a   Romano, Mario R ^b   Danzi, Paola ^a   Morescalchi, Francesco ^a   Costagliola, Ciro ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Anti VEGF therapy; Central serous chorioretinopathy; Intravitreal bevacizumab; Retinal pigment epithelium detachment

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; ARTICLE; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FUNCTIONAL ASSESSMENT; HUMAN; INTERVENTION STUDY; LOW FLUENCE PHOTODYNAMIC THERAPY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINAL THICKNESS; TREATMENT RESPONSE; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOCHEMOTHERAPY; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84872175105     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0162-3     Document Type: Article

References (12)

1. Sahu DK, Namperumalsamy P, Hilton GF, de Sousa NF. Bullous variant of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2000;84:485-92. (Pubitemid 30251709)
2. Rasouli M, Leung D, Gale JS. A unique presentation of bilateral central serous chorioretinopathy following bilateral renal transplantation surgery. Can J Ophthalmol. 2008;43:486-8.
3. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249-56.
4. Huang WC, Chen WL, Tsai YY, Chiang CC, Lin JM. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye (Lond). 2009;23:488-9.
5. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, Ustariz-Gonzales O, Abraham-Marin M, Ober MD, et al. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008;246:1235-9.
6. Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19-24. (Pubitemid 41070746)
7. Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond). 2008;22:100-6.
8. Stewart JM. Half dose verteporfin PDT for central serous chorioretinopathy. Br J Ophthalmol. 2006;90:805-6. (Pubitemid 43973978)
9. Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149:307-15.
10. Wu ZHY, Lai RYK, Yip YWY, Chan WM, Lam DSC, Lai TYY. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina. 2011;31:1378-86. doi:10.1097/FTD.0b013e31820beb02.
11. Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011;31:119-26.
12. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288-98. (Pubitemid 36792972)